---
layout: default
title: Alpha -Tocopherol Acetate Dl- Beta -Carotene Calci
parent: 僅模型預測 (L5)
nav_order: 230
evidence_level: L5
indication_count: 0
---

# Alpha -Tocopherol Acetate Dl- Beta -Carotene Calci
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multivitamin-Mineral Combination: Drug Repurposing Evaluation Report

---

## One-Sentence Summary

This candidate is a 14-component multivitamin and mineral combination (including Vitamins B1, B2, B3, B5, B6, B9, B12, C, D3, E, beta-carotene, calcium carbonate, ferrous fumarate, and zinc oxide), which currently holds **no US market authorization** in the Evidence Pack provided. The TxGNN model returned **no predicted indications**, most likely because the multi-ingredient string could not be resolved to a single DrugBank ID. Accordingly, **no clinical trial or literature evidence** for a repurposing direction is available at this time.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not established (no regulatory records found) |
| Predicted New Indication | None identified |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — Model prediction unavailable; no supporting studies |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

No TxGNN prediction was generated for this candidate, so a mechanistic rationale for a specific new indication cannot be provided. The underlying reason is most likely a pipeline mapping failure: the drug query string consists of 14 semi-colon-delimited ingredients rather than a single international non-proprietary name (INN), which prevented resolution to a DrugBank ID—a prerequisite for both the knowledge-graph (KG) and deep-learning (DL) prediction steps.

Each individual component of this combination is a well-characterised micronutrient (B-complex vitamins, fat-soluble vitamins A/D/E, ascorbic acid, and trace minerals iron/zinc/calcium). As a class, such multivitamin-mineral products are widely used as dietary supplements or adjunctive nutritional support and are not typically entered into the TxGNN repurposing workflow as single-drug candidates. Meaningful repurposing analysis would require either selecting one active ingredient as the primary candidate or querying each component individually.

Because no prediction exists, the current evidence base is entirely absent. A repurposing hypothesis would need to be established manually before any further evaluation is possible.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## US Market Information

No US market authorizations found for this drug combination.

---

## Safety Considerations

Please refer to the package insert for safety information.

> **Note:** No Taiwan regulatory records (仿單) were retrieved for this combination. Individual component safety profiles can be found in each ingredient's respective monograph. Drug-drug interaction data was not found for this multi-ingredient query string.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The TxGNN pipeline was unable to generate any repurposing prediction because the 14-ingredient query string could not be resolved to a DrugBank identifier, leaving zero evidence for any new indication. Without a defined drug entity, mechanistic analysis, regulatory review, and evidence synthesis are all blocked.

**To proceed, the following is needed:**

- **Drug identification**: Determine which single active ingredient is the intended repurposing candidate, or split the combination into individual component queries (e.g., query folic acid, cyanocobalamin, or cholecalciferol separately).
- **DrugBank mapping**: Resolve the selected ingredient(s) to a valid DrugBank ID to enable KG and DL predictions.
- **Regulatory review**: If the target market is the US, verify whether any individual component has existing FDA/NDA records that could inform repurposing strategy.
- **MOA data**: Once the primary ingredient is identified, retrieve its mechanism of action from DrugBank or primary literature.
- **Re-run the pipeline**: After mapping is resolved, re-execute the full TxGNN evidence pack generation to obtain a scoreable prediction and supporting evidence.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

